Top Markets
Coin of the day
Venus Medtech (Hangzhou) Inc. Venus Medtech (Hangzhou) Inc.

Venus Medtech (Hangzhou) Inc.

2500
株式のランク #24714
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the... Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.
株価
$0.13048475
時価総額
$57.55M
変化(1日)
-1.92%
変化(1年)
-77.88%
CN
取引 Venus Medtech (Hangzhou) Inc. (2500)

カテゴリー

Venus Medtech (Hangzhou) Inc.(2500)の収益
Aug 2026 時点の収益 TTM: 0
Venus Medtech (Hangzhou) Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Venus Medtech (Hangzhou) Inc. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。